Active, not recruitingPhase 2NCT03233347

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Studying Classic Hodgkin lymphoma

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Academic and Community Cancer Research United
Principal Investigator: Steven I Park
Academic and Community Cancer Research United
Intervention: Brentuximab Vedotin(drug)
Enrollment: 82 enrolled
Eligibility: 18-60 years · All sexes
Timeline: 2017 – 2026

Study locations (9)

City of Hope Comprehensive Cancer Center, Duarte, California, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
M D Anderson Cancer Center, Houston, Texas, United States
University of Washington Medical Center - Montlake, Seattle, Washington, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03233347 on ClinicalTrials.gov

Other trials for Classic Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Classic Hodgkin lymphoma →

← Back to all trials